Oncology

Breast cancer communication varied by race, with Black women rating staff interactions lower than White women in a Brazilian study.

Combining targeted bispecific therapy with checkpoint blockade in head and neck cancer demonstrates considerable survival benefits.

Adding pembrolizumab to chemotherapy extends progression-free survival in advanced breast cancer after any prior endocrine therapy.

Growth hormone secretagogues raise physiological growth factors, demanding vigilant clinical evaluation regarding potential oncologic risks.

Ivonescimab combined with chemotherapy significantly improves overall survival for patients with advanced biliary tract cancer.

Darolutamide combined with androgen-deprivation therapy significantly delays disease progression in metastatic hormone-sensitive prostate cancer without requiring chemotherapy.

Early relapse within three months following definitive therapy dramatically reduces long-term survival in oral tongue cancer.

Colorectal cancer progressively surpasses other prevalent malignancies as the principal cause of mortality among younger Americans.